In patients with stage I–III colorectal cancer, the 5-year disease-specific survival (DSS) rate was significantly lower in the high CEA group compared to the low CEA group (<5 ng/mL) (76.1% vs. 98.5%, p < 0.001; Figure 3). Here, CEACAM5 is linked to colorectal cancer.